Motif Bio PLC Presentation of Two Posters on Iclaprim
29 Settembre 2015 - 8:02AM
RNS Non-Regulatory
TIDMMTFB
Motif Bio PLC
29 September 2015
29 September 2015
Motif Bio plc
("Motif" or the "Company")
Announces Presentation of Two Posters on Iclaprim at ID Week
2015
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical
company specialising in developing novel antibiotics, today
announced that data from two iclaprim clinical studies have been
accepted for presentation at the Infectious Disease Week 2015 (ID
Week) conference in San Diego, California which runs from the 7(th)
to the 11(th) of October 2015. Iclaprim is a novel antibiotic,
targeting the bacterial dihydrofolate reductase enzyme, currently
beginning two Phase III studies to treat acute bacterial skin and
skin structure infections (ABSSSI).
The two posters:
(1) "Cessation of Spread of Lesion and Absence of Fever at 72
hours in Complicated Skin and Skin Structure Infection (cSSSI):
Reanalysis of the Combined ASSIST Phase III Studies Comparing
Iclaprim (ICL) and Linezolid (LZD)."
Skin and skin structure infections (SSSI) are a challenging
medical problem associated with high direct and indirect costs to
both medical systems and society. Infection due to bacteria with
resistance to previously effective antimicrobials such as MRSA are
highly prevalent and have led to high rates of complications and
hospitalization. This poster presents data on the reanalysis of the
Phase III cSSSI studies comparing iclaprim to linezolid, a standard
of care treatment of SSSI, using endpoints similar to the FDA's
recently changed guidelines for ABSSSI trials.
(2) "Randomized, Double-Blind, Multicenter Phase II Study to
Evaluate Efficacy and Safety of Intravenous Iclaprim (ICL) versus
Vancomycin in the Treatment of Hospital-Acquired,
Ventilator-Associated, or Health-Care-Associated Pneumonia
Suspected or Confirmed Caused by Gram-positive Pathogens."
Hospital-acquired bacterial pneumonia (HABP), including
ventilator-associated pneumonia (VAP), and healthcare-associated
pneumonia (HCAP) are commonly caused by Staphylococcus aureus,
including MRSA. Despite the available antibiotics to treat HABP,
VAP, and HCAP, clinical failures occur due to infections caused by
antibiotic-resistant bacteria, intolerance to drugs due to adverse
events, or reduced penetration of drugs at the site of infection.
It is estimated that an average of 30% (ranging from 14%-50%) of
HABP cases will result in death directly attributable to this
infection. This poster presents data on outcomes related to
treatment with iclaprim compared to vancomycin, a standard of care
treatment of HABP, VAP and HCAP.
The posters will be presented on 9 October 2015 at 12:30 PM -
2:00 PM at the San Diego Convention Center Poster Hall.
Enquiries
Motif Bio plc info@motifbio.com
Graham Lumsden (Chief Executive
Officer)
David Huang (Chief Medical Officer)
www.motifbio.com
Zeus Capital Limited (NOMINATED
ADVISER and BROKER)
Phil Walker/ John Treacy +44 (0) 20
Dominic Wilson 7533 7727
Northland Capital Partners Limited
(BROKER)
Patrick Claridge/ David Hignell +44 (0) 20
John Howes/ Mark Treharne (Broking) 7382 1100
+49 (0) 89
MC Services AG (TRADE PR) 210 2280
Raimund Gabriel +44 (0) 207
Shaun Brown 148 5998
Plumtree Capital Limited (FINANCIAL
ADVISOR) +44 (0) 207
Stephen Austin 183 2493
Yellow Jersey PR Limited (FINANCIAL
PR)
Charles Goodwin +44 (0) 7747
Dominic Barretto 788 221
Notes to Editors:
Motif is a clinical stage biopharmaceutical company, which
specialises in developing novel antibiotics designed to be
effective against serious and life-threatening infections caused by
multi-drug resistant bacteria.
Iclaprim is being developed for the treatment of the most common
and serious bacterial infections such as acute bacterial skin and
skin structure infections (ABSSSI) and hospital acquired bacterial
pneumonia (HABP), including those caused by resistant strains such
as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP
(multi-drug resistant Streptococcus pneumoniae) that have become
prevalent in patients in both the community and hospital
settings.
The Company is in discussions with pharmaceutical companies and
universities to build a pipeline of innovative antibiotics
targeting Gram-positive and Gram-negative bacteria.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAPKFDBKBKBKCB
(END) Dow Jones Newswires
September 29, 2015 02:02 ET (06:02 GMT)
Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Lug 2023 a Lug 2024